APC 2

Drug Profile

APC 2

Alternative Names: APC2; MB 102; MP-3180; PP 2338

Latest Information Update: 22 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mallinckrodt Inc.
  • Developer MediBeacon
  • Class Diagnostic agents; Pyrazines; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute kidney injury
  • Clinical Phase Unknown Kidney disorders

Most Recent Events

  • 03 Mar 2017 MediBeacon completes a clinical trial in Kidney disorders in USA
  • 02 Mar 2017 MediBeacon completes a phase II trial in Acute kidney injury (Diagnosis) in USA (IV)
  • 02 Mar 2017 MediBeacon plans a multicentre clinical study for Kidney disorders in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top